Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | WT2725 |
Synonyms | |
Therapy Description |
WT2725 is a oligopeptide vaccine that induces WT1-specific cytotoxic T-lymphocytes, potentially resulting in antitumor activity against WT1-positive tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
WT2725 | WT2725 is a oligopeptide vaccine that induces WT1-specific cytotoxic T-lymphocytes, potentially resulting in antitumor activity against WT1-positive tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 2066-2066). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |